Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Computerized Thermal Imaging CIO (formerly COII) -- Ignore unavailable to you. Want to Upgrade?

To: pilapir who wrote (6004)	5/28/2002 10:01:34 PM
From: StockDung	Read Replies (3) \| Respond to of 6039

Cauley Geller Bowman & Coates, LLP Announces Class Action Lawsuit Against Computerized Thermal Imaging, Inc. on Behalf of Investors LITTLE ROCK, Ark., May 28 /PRNewswire-FirstCall/ -- The Law Firm of Cauley Geller Bowman & Coates, LLP announced today that a class action has been filed in the United States District Court for the District of Oregon on behalf of purchasers of Computerized Thermal Imaging (Amex: CIO) ("CTI" or the "Company") common stock during the period between October 11, 1999 and December 21, 2001, inclusive (the "Class Period"). A copy of the complaint filed in this action is available from the Court, or can be viewed on the firm's website at classlawyer.com . The complaint charges Computerized Thermal Imaging, Inc. and certain of its officers and directors with issuing false and misleading statements concerning its business and financial condition. Specifically, the complaint alleges that CTI has admitted that during the Class Period, the Company's then-President and Chief Operating Officer, David Packer, consistently made material public misrepresentations regarding FDA approval of the Company's Breast Cancer Detection System. These statements had the effect of artificially raising the price of CTI stock so that investors who purchased CTI shares during the Class Period did so at inflated prices and were damaged thereby. If you bought CTI common stock between October 11, 1999 and December 21, 2001, inclusive, and you wish to serve as lead plaintiff, you must move the Court no later than July 9, 2002. If you are a member of this class, you can join this class action online at classlawyer.com . Any member of the purported class may move the Court to serve as lead plaintiff through Cauley Geller Bowman & Coates, LLP or other counsel of their choice, or may choose to do nothing and remain an absent class member. Cauley Geller Bowman & Coates, LLP has substantial experience representing investors in securities fraud class action lawsuits such as this. The firm has offices in Florida and Arkansas, but represents investors throughout the nation. If you have any questions about how you may be able to recover for your losses, or if you would like to consider serving as one of the lead plaintiffs in this lawsuit, you are encouraged to call or e-mail the Firm or visit the Firm's website at www.classlawyer.com . CAULEY GELLER BOWMAN & COATES, LLP Investor Relations Department: Jackie Addison, Sue Null or Shelly Nicholson P.O. Box 25438 Little Rock, AR 72221-5438 Toll Free: 1-888-551-9944 E-mail: info@classlawyer.com MAKE YOUR OPINION COUNT - Click Here tbutton.prnewswire.com SOURCE Cauley Geller Bowman & Coates, LLP CO: Cauley Geller Bowman & Coates, LLP; Computerized Thermal Imaging, Inc. ST: Arkansas, Oregon SU: LAW prnewswire.com 05/28/2002 15:39 EDT

To: pilapir who wrote (6004)	12/12/2002 3:30:11 PM
From: StockDung	Respond to of 6039

Computerized Thermal's Secord Sold Stock Just Before FDA Action Lake Oswego, Oregon, Dec. 12 (Bloomberg) -- Chief Executive Officer Richard V. Secord sold 111,300 shares of Computerized Thermal Imaging Inc. on Monday and Tuesday, hours before a panel of scientists voted Tuesday to recommend against U.S. Food and Drug Administration approval of the Computerized Thermal's flagship breast cancer detection system. Secord is a former Reagan Administration official and a retired U.S. Air Force general whose guilty plea in 1989 for lying to Congress about his conduct in the Iran-Contra affair was overturned in 2000. He sold the shares as the company's stock reached its highest level in six months, according to a filing with the Securities and Exchange Commission yesterday. Within hours of his last trade Tuesday, the American Stock Exchange halted trading, after a one-day drop of 63 percent. Panel member Geoffrey Ibbott, associate professor at the University of Texas MD Anderson Cancer Center's department of radiation physics in Houston, said in an interview that the company's upbeat briefing Monday on results of its clinical trials was misleading. Securities lawyers questioned the timing of Secord's stock sale. ``Selling that much stock at that time was an unbelievably stupid thing to do,'' said Frank Partnoy, professor of securities law at the University of San Diego School of Law. Partnoy said it's likely the Securities and Exchange Commission will investigate Secord's trades. ``The SEC is very busy and just got a little busier.'' Secord, 70, declined comment on his stock sale, said company spokeswoman Kristy Cory. Details of Sales Secord sold stock of the Lake Oswego, Oregon-based company at an average price of $1.14, according to the SEC filing. The stock closed yesterday at 33 cents. After selling 73,400 shares on Monday, he sold another 37,900 on Tuesday, representing 27 percent of his 415,286 shares, according to the SEC filing. Shares rose 3 cents to 36 cents at 1:15 p.m. New York Time. The retired major general, whose resume includes 285 combat missions while serving in Southeast Asia in the 1960s, served as deputy assistant secretary of defense for international security affairs from 1981 to 1983. In August 2000, in response to a motion by Secord's lawyer, the U.S. District Court for the District of Columbia expunged Secord's guilty plea in the Iran-Contra case. The shares rose as high as $1.29 on Monday after the FDA released a company-written summary of clinical studies on more than 2,400 women over about five years. ``Based on the results of the study, approximately one out of five who had benign masses who otherwise would have gone to biopsy would have been spared the need for a biopsy on a benign mass,'' the company said. FDA reviewer William Sacks said he had a different interpretation of the data. He said he told the panel on Tuesday that the device could remove the need for between 5 and 7 percent of biopsies. Misleading Data Panel member Ibbott of MD Anderson said he voted against approval. He said Computerized Thermal's summary distorted its clinical results by omitting patients who were prescribed biopsies because of abnormalities other than masses in their mammograms. ``They carefully selected the data that showed their device in the best light and omitted the less favorable data,'' Ibbott said. ``To completely leave them out is misleading. It suggests the device is useful for a larger population of women than is actually the case.'' The FDA panel voted 4-3 Tuesday to recommend the agency deny approval of the company's BCS 2100 breast scanner. The device could have benefits, and Computerized Thermal should continue to study it, panel members said. Ibbott said even if the panel had approved the scanner, it would have been conditioned on Computerized Thermal conducting additional studies. ``It would not really have meant much difference for the company,'' he said. Last year, Computerized Thermal accused its former president of tampering with results of the breast cancer detection device's clinical trials, and misleading shareholders about the status of the FDA application. The company held its annual shareholders meeting today at the boardroom American Stock Exchange in New York. --David Evans in Los Angeles (323)782-4241 or at davidevans@bloomberg.net Editors: Neumann, Henkoff. Story illustration: For information on Computerized Thermal Imaging, see CIO US <Equity> CNP06775180105 <GO> . For top health-care news, see: HTOP <GO> .